Research & Publications
Dr. Kim specializes in early phase clinical trials of novel cancer therapies.
Extensive Research Description
Dr. Kim specializes in early phase clinical trials of novel cancer therapies. Dr. Kim's research interests include DNA repair pathway, mTOR pathway, tumor hypoxia, cancer immunotherapy. Dr. Kim is currently spearheading several NCI-sponsored clinical trials of PARP inhibitor, olaparib in combination wtih a VEGFR tyrosine kinase inhibitor, cediranib, in prostate cancer (CTEP# 9984) and in other advanced solid tumors (CTEP #9881) as well as a mTOR inhibitor, sapanisertib (aka TAK228 or MLN0128) for advanced urinary tract cancers (CTEP #9767) as the Study Chair.
Clinical Trials - Early Phase; Cancer therapies; DNA Repair Pathways; mTOR pathways; Cancer immunotherapy